These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34366886)

  • 41. The relationship between advanced liver fibrosis and osteoporosis in type 2 diabetes patients with MAFLD.
    Pan B; Zhao Y; Chen C; Cai J; Li K; Wang Y; Liu J
    Endocrine; 2024 Jul; 85(1):206-221. PubMed ID: 38367145
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation between Serum 25 (OH) D Levels with Insulin Resistance and Metabolic Associated Fatty Liver Disease - A Retrospective Study based on Chinese Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
    Zhao X; Sun J; Xin S; Xu X; Zhang X
    Curr Diabetes Rev; 2024 Jul; ():. PubMed ID: 38956910
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship Between Serum Uric Acid-to-Creatinine Ratio and the Risk of Metabolic-Associated Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus.
    Xing Y; Chen J; Liu J; Song G; Ma H
    Diabetes Metab Syndr Obes; 2022; 15():257-267. PubMed ID: 35140486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease.
    Su W; Chen M; Xiao L; Du S; Xue L; Feng R; Ye W
    Front Public Health; 2022; 10():1047794. PubMed ID: 36420005
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blood lactate levels are associated with an increased risk of metabolic dysfunction-associated fatty liver disease in type 2 diabetes: a real-world study.
    Ma YL; Ke JF; Wang JW; Wang YJ; Xu MR; Li LX
    Front Endocrinol (Lausanne); 2023; 14():1133991. PubMed ID: 37223022
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies.
    Soltani S; Beigrezaei S; Malekahmadi M; Clark CCT; Abdollahi S
    BMC Endocr Disord; 2023 Apr; 23(1):73. PubMed ID: 37029398
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment.
    Ding Y; Deng Q; Yang M; Niu H; Wang Z; Xia S
    Diabetes Metab Syndr Obes; 2023; 16():3303-3329. PubMed ID: 37905232
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease from clinical to pathological characteristics: a multi-center cross-sectional study in real world.
    Li Y; Dai C; Ruan Y; Yang H; Zeng H; Huang R; Wang J; Dai M; Hao J; Wang L; Li J; Yan X; Lu Z; Ji F
    Postgrad Med J; 2024 Apr; 100(1183):319-326. PubMed ID: 38272486
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum adropin level is associated with endothelial dysfunction in patients with obstructive sleep apnea and hypopnea syndrome.
    Fan Z; Zhang Y; Zou F; Xu T; Pan P; Hu C; Su X
    Sleep Breath; 2021 Mar; 25(1):117-123. PubMed ID: 32253609
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
    Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
    Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus.
    Bhardwaj M; Mazumder PM
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; ():. PubMed ID: 38861011
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure.
    Berezin AA; Obradovic Z; Fushtey IM; Berezina TA; Novikov EV; Schmidbauer L; Lichtenauer M; Berezin AE
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36830993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The association of serum and vitreous adropin concentrations with diabetic retinopathy.
    Li S; Sun J; Hu W; Liu Y; Lin D; Duan H; Liu F
    Ann Clin Biochem; 2019 Mar; 56(2):253-258. PubMed ID: 30514096
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prediction and Validation of Metabolic Dysfunction-Associated Fatty Liver Disease Using Insulin Resistance-Related Indices in the Japanese Population.
    Moriyama K; Inoue N; Imai J; Masuda Y; Yamada C; Kishimoto N; Takashimizu S; Kubo A; Nishizaki Y
    Metab Syndr Relat Disord; 2023 Nov; 21(9):489-496. PubMed ID: 37878804
    [No Abstract]   [Full Text] [Related]  

  • 55. Novel associations of serum adropin and lipopolysaccharide-binding protein versus lipid profiles in childhood obesity.
    Yuan X; Chen R; Ouyang Q; Lin X; Ai Z; Zhang Y; Yang X
    J Pediatr Endocrinol Metab; 2020 Feb; 33(2):265-270. PubMed ID: 31953997
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
    Hu Q; Chen Y; Bao T; Huang Y
    Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum Adropin Levels in Patients with Rheumatoid Arthritis.
    Simac P; Perkovic D; Bozic I; Bilopavlovic N; Martinovic D; Bozic J
    Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207457
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Associations of sex-related and thyroid-related hormones with risk of metabolic dysfunction-associated fatty liver disease in T2DM patients.
    Lu W; Li S; Li Y; Zhou J; Wang K; Chen N; Li Z
    BMC Endocr Disord; 2024 Jun; 24(1):84. PubMed ID: 38849804
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation of the pediatric metabolic index with NAFLD or MAFLD diagnosis, and serum adipokine levels in children.
    Lazo-de-la-Vega-Monroy ML; Preciado-Puga MD; Ruiz-Noa Y; Salum-Zertuche M; Ibarra-Reynoso LD
    Clin Res Hepatol Gastroenterol; 2023 May; 47(6):102137. PubMed ID: 37149032
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum metabolomics-based heterogeneities and screening strategy for metabolic dysfunction-associated fatty liver disease (MAFLD).
    Shao L; Liu J; Song Y; Yang W; Gong L; Lyu Z; Zhu Q; Fu J; Li J; Shi J
    Clin Chim Acta; 2023 Jan; 538():203-210. PubMed ID: 36549641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.